Endonovo Therapeutics, Inc.
ENDV
Price:
$0.0014
Market Cap:
$446.25K
Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of inflammation, wounds, cardiovascular diseases, chronic kidney diseases, liver diseases, non-alcoholic steatohepatitis, peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concuss...[Read more]
Industry
Biotechnology
IPO Date
2012-11-15
Stock Exchange
PNK
Ticker
ENDV
The ROE as of September 2024 (TTM) for Endonovo Therapeutics, Inc. (ENDV) is 15.62%
According to Endonovo Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 15.62%. This represents a change of 298.36% compared to the average of 3.92% of the last 4 quarters.
Endonovo Therapeutics, Inc. (ENDV) Historical ROE (quarterly & annually)
How has ENDV ROE performed in the past?
The mean historical ROE of Endonovo Therapeutics, Inc. over the last ten years is 54.42%. The current 15.62% ROE has changed -71.31% with respect to the historical average. Over the past ten years (40 quarters), ENDV's ROE was at its highest in in the March 2017 quarter at 59.43%. The ROE was at its lowest in in the March 2023 quarter at -60.24%.
Average
54.42%
Median
59.29%
Minimum
-28.73%
Maximum
114.15%
Endonovo Therapeutics, Inc. (ENDV) ROE by Quarter and Year
Discovering the peaks and valleys of Endonovo Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 289.32%
Maximum Annual ROE = 114.15%
Minimum Annual Increase = -128.76%
Minimum Annual ROE = -28.73%
| Year | ROE | Change |
|---|---|---|
| 2023 | -28.73% | -128.76% |
| 2022 | 99.87% | 289.32% |
| 2021 | 25.65% | 81.94% |
| 2020 | 14.10% | -87.65% |
| 2019 | 114.15% | 102.05% |
| 2018 | 56.50% | -50.09% |
| 2017 | 113.19% | 82.32% |
| 2016 | 62.09% | -7.23% |
| 2015 | 66.92% | 227.33% |
| 2014 | 20.45% | -70.80% |
Endonovo Therapeutics, Inc. (ENDV) Average ROE
How has ENDV ROE performed in the past?
The current ROE of Endonovo Therapeutics, Inc. (ENDV) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
32.27%
5-year avg
45.01%
10-year avg
54.42%
Endonovo Therapeutics, Inc. (ENDV) ROE vs. Peers
How is ENDV’s ROE compared to its peers?
Endonovo Therapeutics, Inc.’s ROE is greater than Bio-Path Holdings, Inc. (-2842.40%), less than Cingulate Inc. (11.47%), greater than Purple Biotech Ltd. (-48.16%), greater than Soleno Therapeutics, Inc. (-43.25%), less than Genelux Corporation (0%), greater than Comera Life Sciences Holdings, Inc. (-110.28%), less than Dyadic International, Inc. (1.54%), greater than Monopar Therapeutics Inc. (-145.95%), greater than Cellectis S.A. (-110.60%), greater than Biotron Limited (-81.02%), greater than Bioasis Technologies Inc. (-592.92%), greater than Covalon Technologies Ltd. (0%), greater than Mosaic ImmunoEngineering Inc. (-4.23%), less than Quoin Pharmaceuticals, Ltd. (13.27%), greater than Bolt Biotherapeutics, Inc. (-112.11%), greater than Pasithea Therapeutics Corp. (-61.40%), greater than MediciNova, Inc. (-74.63%), greater than Fresh Tracks Therapeutics, Inc. (-13.37%), greater than null (-58.16%),
| Company | ROE | Market cap |
|---|---|---|
| -2842.40% | $2.53M | |
| 11.47% | $11.22M | |
| -48.16% | $10.79M | |
| -43.25% | $2.13B | |
| 0% | $83.77M | |
| -110.28% | $682.38K | |
| 1.54% | $35.52M | |
| -145.95% | $15.47M | |
| -110.60% | $183.12M | |
| -81.02% | $10.06M | |
| -592.92% | $291.93K | |
| 0% | $58.92M | |
| -4.23% | $7.24M | |
| 13.27% | $2.24M | |
| -112.11% | $23.94M | |
| -61.40% | $5.42M | |
| -74.63% | $81.91M | |
| -13.37% | $4.66M | |
| -58.16% | $0 |
Build a custom stock screener for Endonovo Therapeutics, Inc. (ENDV) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Endonovo Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Endonovo Therapeutics, Inc. (ENDV) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Endonovo Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Endonovo Therapeutics, Inc.'s ROE?
How is the ROE calculated for Endonovo Therapeutics, Inc. (ENDV)?
What is the highest ROE for Endonovo Therapeutics, Inc. (ENDV)?
What is the 3-year average ROE for Endonovo Therapeutics, Inc. (ENDV)?
What is the 5-year average ROE for Endonovo Therapeutics, Inc. (ENDV)?
How does the current ROE for Endonovo Therapeutics, Inc. (ENDV) compare to its historical average?